Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

OncLive’s October EMA Regulatory Recap: Key EU Approvals in Oncology

November 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.

Five Under 5: Top Oncology Videos for the Week of 10/26

November 2nd 2025

The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 10/26

November 1st 2025

Belzutifan-based combinations meet end points in RCC, imaging agent under review for SSTR-positive neuroendocrine tumors, and more.

Federal Funding Cuts Hit Cancer Research Despite Public Support

October 31st 2025

Primo Nery Lara, Jr., MD, and Suneel Kamath, MD, discuss the effects of federal cuts to cancer research despite public support for funding this research.

OncLive’s October Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 31st 2025

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

The Future of Pathology with AI: Future Directions and Clinical Implementation

October 30th 2025

Experts envision AI rapidly analyzing digitized pathology slides to assist diagnosis, highlight uncertainties, assess tumor heterogeneity, and more.

The Future of Pathology With AI: Predicting Prognosis and Personalized Treatment

October 30th 2025

The Future of Pathology With AI: Molecular Subtyping and Genetic Testing

October 30th 2025

Experts discuss how AI can rapidly predict molecular subtypes from H&E slides with 87% accuracy, enhancing but not replacing genomic testing.

The Future of Pathology With AI: Practical Applications

October 30th 2025

Experts discuss how AI can diagnose cancer from standard H&E slides while accounting for slide quality differences to support broader clinical use.

The Future of Pathology With AI: Setting the Stage

October 30th 2025

Experts provide an overview of AI's integration into modern pathology and the development of foundation models for cancer diagnosis.

Frontline Darovasertib Plus Crizotinib Shows Clinical Efficacy in Metastatic Uveal Melanoma

October 28th 2025

Darovasertib plus crizotinib improved OS to 21.1 months and boosted response rates in first-line metastatic uveal melanoma vs historical approaches.

VERITAC-2 PRO Data Support Potential of Vepdegestrant in ESR1-Mutated ER+ Advanced Breast Cancer

October 28th 2025

Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.

FDA Awards Fast Track Designation to MT-125 for Glioblastoma

October 28th 2025

FDA grants fast track status to MT-125, a first-in-class NMII inhibitor, aiming to bring a novel treatment option to patients with aggressive glioblastoma.

ELI-002 7P Shows Potential to Address Unmet Need in Pancreatic Ductal Adenocarcinoma

October 27th 2025

Specific HLA types were not found to be associated with robust mKRAS-specific T-cell responses after treatment with ELI-002 7P in patients with PDAC.

EVX-01 Plus Pembrolizumab Drives Durable Disease Control, T-Cell Responses in Advanced Melanoma

October 27th 2025

EVX-01 plus pembrolizumab generated an overall response rate of 75% and durable T-cell responses in advanced melanoma.

Neladalkib Showcases Early Activity in ALK+ Solid Tumors

October 27th 2025

Neladalkib showed durable responses and good tolerability in ALK-positive solid tumors, including TKI-pretreated patients, in early ALKOVE-1 results.

Five Under 5: Top Oncology Videos for the Week of 10/19

October 26th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer and lung cancer.

The OncFive: Top Oncology Articles for the Week of 10/19

October 25th 2025

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

Cadonilimab Plus Chemo Retains Clinically Meaningful Survival Advantage in Frontline Gastric/GEJ Adenocarcinoma

October 23rd 2025

First-line cadonilimab plus chemotherapy demonstrated long-term efficacy benefits vs chemotherapy alone in patients with advanced gastric or GEJ adenocarcinoma.

PRO Data Further Support SERENA-6 Regimen in HR+ Breast Cancer After Emergence of ESR1 Mutations

October 22nd 2025

Switching to camizestrant plus a CDK4/6 inhibitor delayed symptom deterioration and improved QOL in HR+ breast cancer with the emergence of ESR1 mutations.